Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (7) , 1816-1827
Abstract
Background: Studies have reported that advanced NSCLC benefits from celecoxib combined with systematic treatment. However, the optimal combination with different treatments remains unclear. A meta-analysis was conducted to explore treatment combinations.Keywords
This publication has 62 references indexed in Scilit:
- Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinomaDrug Design, Development and Therapy, 2013
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and DocetaxelClinical Cancer Research, 2005
- Chemotherapy Induces the Expression of Cyclooxygenase-2 in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trialLung Cancer, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Inflammation and cancerNature, 2002